長谷川 直樹

Medicine & Life Sciences

1. Mycobacterium avium Complex 100%
2. Lung Diseases 68%
3. Lung 51%
4. Acute Lung Injury 49%
5. Japan 47%
6. Coronavirus 39%
7. SARS Virus 29%
8. Bronchoalveolar Lavage Fluid 24%
9. Infections 24%
10. Endotoxins 24%
11. Mycobacterium abscessus 20%
12. Clarithromycin 18%
13. Severe Acute Respiratory Syndrome 18%
14. Pneumonia 17%
15. Mycobacterium avium 16%
16. Adult Respiratory Distress Syndrome 16%
17. Hematopoietic Stem Cell Transplantation 15%
18. Serum 15%
19. Mycobacterium 15%
20. Interstitial Lung Diseases 14%
21. Nontuberculous Mycobacteria 14%
22. Therapeutics 13%
23. Tokyo 12%
24. Tuberculosis 12%
25. Antibodies 11%
26. Vaccination 11%
27. Neutrophils 11%
28. Lipopolysaccharides 10%
29. Macrolides 10%
30. Pneumococcal Infections 10%
31. Lung Injury 10%
32. Amikacin 9%
33. Interleukin-6 9%
34. Pneumocystis Pneumonia 9%
35. Polymerase Chain Reaction 9%
36. Safety 9%
37. Drug Therapy 9%
38. Cross-Sectional Studies 8%
39. Health Personnel 8%
40. Vaccines 8%
41. Advisory Committees 8%
42. Elderly 8%
43. human MIRN346 microRNA 8%
44. Bacteremia 8%
45. Mycobacterium Infections 8%
46. Ethambutol 8%
47. Sepsis 8%
48. Sputum 8%
49. Pancreatic Elastase 8%
50. Mycobacterium tuberculosis 7%